A Radnor biopharma firm saw its stock price skyrocket after the company posted positive late-stage clinical trial results for ...
In a report released yesterday, Tim Anderson from Bank of America Securities maintained a Buy rating on Mineralys Therapeutics, Inc. (MLYS – ...
NASDAQ MLYS opened at $14.30 on Wednesday. The stock’s fifty day moving average price is $10.35 and its 200-day moving average price is $11.90. Mineralys Therapeutics, Inc. has a 12 month low of ...
Mineralys Therapeutics (Nasdaq: MLYS) saw its stock rise by over 40% after reporting positive top-line results from two ...
Mineralys Therapeutics (MLYS) announced positive topline data from its Launch-HTN Phase 3 and Advance-HTN Phase 2 trials evaluating the ...
Primary endpoints of both Advance-HTN and Launch-HTN studies, using lorundrostat to treat patients with hypertension were met ...
Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea ...
Positive top-line data from phase II and III studies of lorundrostat for treating uncontrolled or resistant hypertension ...
MINERALYS THERAPEUTICS ($MLYS) posted quarterly earnings results on Wednesday, February 12th. The company reported earnings of -$0.98 per share, beating estimates of ...
Goldman Sachs analyst Richard Law CFA maintained a Buy rating on Mineralys Therapeutics, Inc. (MLYS – Research Report) on March 7 and set a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback